Recent 8-K filings for ATRC

• May 6, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  AtriCure Q1 revenue $141.2M (+14.3%); corrects FY2026 guidance to rev $600-610M, adj EBITDA $80-82M

  Q1 revenue $141.2M (+14.3% YoY); net income $0.1M, breakeven EPS.

• May 5, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  AtriCure Q1 2026 revenue $141.2M (+14.3%); net income $0.1M; adj. EBITDA $17.1M

  Worldwide revenue $141.2M (+14.3% YoY); U.S. $116.2M (+14.9%), international $25.0M (+11.5%).

• February 17, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  AtriCure Q4 revenue $140.5M (+13.1% YoY); guides FY26 revenue $600-610M

  Q4 2025 revenue $140.5M (+13.1% YoY); net income $1.8M ($0.04 EPS) vs net loss $0.33 per share in Q4 2024.

• January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 1.01item 2.02item 2.03item 9.01 ◈ Material Agreements

  AtriCure reports preliminary Q4 revenue $140.5M (+13%), FY 2025 $534.5M (+15%); guides 2026 revenue ~$600-610M

  Q4 2025 revenue $140.5M (+13% YoY); US $114.3M (+13%), intl $26.2M (+15% as reported).

• October 29, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  AtriCure Q3 revenue $134.3M (+15.8% YoY); net loss narrows to $0.3M; raises FY2025 outlook

  Revenue $134.3M, +15.8% YoY (+15.1% constant currency); US $109.3M (+14.5%), intl $25.0M (+22.0%).

• October 29, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  AtriCure Q3 revenue +15.8% to $134.3M, net loss narrows to $0.3M; raises 2025 outlook

  Revenue of $134.3M (+15.8% YoY); U.S. $109.3M (+14.5%), international $25.0M (+22.0%).

• July 29, 2025, 7:59 PM ET earnings materiality 0.78 positive item 2.02item 9.01

  AtriCure Q2 revenue up 17%; net loss narrows; raises 2025 outlook

  Worldwide revenue $136.1M (+17.1% YoY); U.S. $110.6M (+15.7%), Int'l $25.6M (+23.3%).

• April 29, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  AtriCure Q1 revenue $123.6M (+13.6% YoY); net loss improves to $6.7M from $13.2M

  Revenue $123.6M (+13.6% YoY; +14.1% constant currency); U.S. $101.1M (+12.1%), International $22.5M (+20.8%).

• February 12, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  AtriCure Q4 revenue $124.3M (+16.6% YoY); guides FY25 rev $517-527M

  Q4 revenue $124.3M (+16.6%); full year revenue $465.3M (+16.5%).

• January 13, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  AtriCure reports preliminary Q4 revenue $124.3M (+17%); guides 2025 revenue $517-527M

  Preliminary Q4 2024 revenue $124.3M (+17% YoY as reported and constant currency).

• October 29, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  AtriCure Q3 2024: revenue $115.9M (+17.9%), loss $0.17/sh, positive cash flow $16.3M

  Worldwide revenue $115.9M, up 17.9% YoY; U.S. $95.5M (+16.8%), Intl $20.5M (+23.3%).

• July 30, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  AtriCure Q2 2024 revenue $116.3M (+15.2% YoY); net loss $0.17/share

  Worldwide revenue $116.3M, up 15.2% YoY (15.4% constant currency); U.S. $95.5M (+12.5%), international $20.7M (+29.4%).

• May 1, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  AtriCure Q1 revenue $108.9M (+16.4% YoY); net loss per share $0.28

  Worldwide revenue $108.9M, up 16.4% YoY (16.3% constant currency); U.S. revenue $90.2M (+15.4%), international $18.6M (+21.5%).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.78 · Median 0.70 · Most common event earnings

11 positive 0 negative 7 neutral

source · ATRC on sec.gov